Clinical Utilization of Non-Anticoagulant - A Review
Pitchaimuthu Pandian1★★ Corresponding author
- 1Department of Pharmacy, Annamalai University, Annamalainagar, Tamil Nadu, INDIA.
CORRESPONDENCE
Pitchaimuthu Pandian
Department of Pharmacy, Annamalai University, Annamalainagar, Tamil Nadu, INDIA.
Received: 17-05-2020; Revised: 26-07-2020; Accepted: 05-09-2020.
Volume 10, Issue 4 · pp. 423–429 · PUBLISHED · DOI: 10.5330/ijpi.2020.4.75
ABSTRACT
Heparin is used as anticoagulant for long period and also other activities both experimentally and clinically. The heparin is prepared by many methods namely enzymatic hydrolysis, chemical hydrolysis by removing the antithrombin binding sites or inactivating functional groups or units of this sequence. In non-anticoagulant treatments the therapeutic spectrum helps to the structural variations to treat different diseases. Sulfated non anticoagulant heparins (S-NACHs) might be preferred for potential clinical use in cancer patients without affecting hemostasis. Among still some of the drugs or its derivatives are undergoing the clinical trials for various non-anticoagulant diseases. This review analyses the effects of this group of drugs on non-anticoagulant heparin, acute pulmonary embolism, oral pulmonary embolism, Non anticoagulant in cancer, Antitumor activities of LMWHs, dermatology, Effects of non-anticoagulant on Fractures such as bone metabolism, bone mineral density, Anti-inflammatory, asthma, Malaria Parasites, Anti-Human Immunodeficiency Virus, Non-anticoagulant activities of LMWHs with their mechanism, Non-anticoagulant pharmacological activities in clinical trials are discussed in this review.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Pandian, P. (). Clinical Utilization of Non-Anticoagulant - A Review. International Journal of Pharmaceutical Investigation, 10(4), 423–429. https://doi.org/10.5330/ijpi.2020.4.75